ESMO: Update on the ENGOT-EN6 RUBY Trial
In this MEDtalk, Mansoor Raza Mirza gives a summary of the study he presented at ESMO last year about the role of immunotherapy in endometrial cancer, the ENGOT-EN6 RUBY trial. Earlier this year, they presented the overall survival data, which has shown a very strong benefit. At this ESMO, he will present further subgroup analyses of efficacy data and patient-reported outcomes analysis in the subgroups.
